TW202034955A - 使用免疫調節治療癌症之新穎方法 - Google Patents

使用免疫調節治療癌症之新穎方法 Download PDF

Info

Publication number
TW202034955A
TW202034955A TW108145197A TW108145197A TW202034955A TW 202034955 A TW202034955 A TW 202034955A TW 108145197 A TW108145197 A TW 108145197A TW 108145197 A TW108145197 A TW 108145197A TW 202034955 A TW202034955 A TW 202034955A
Authority
TW
Taiwan
Prior art keywords
treatment
day
months
pembrolizumab
administered
Prior art date
Application number
TW108145197A
Other languages
English (en)
Chinese (zh)
Inventor
文森 約翰 歐尼爾
Original Assignee
美商百歐克斯賽爾治療公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商百歐克斯賽爾治療公司 filed Critical 美商百歐克斯賽爾治療公司
Publication of TW202034955A publication Critical patent/TW202034955A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
TW108145197A 2018-12-10 2019-12-10 使用免疫調節治療癌症之新穎方法 TW202034955A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862777352P 2018-12-10 2018-12-10
US62/777,352 2018-12-10
US201962924429P 2019-10-22 2019-10-22
US62/924,429 2019-10-22

Publications (1)

Publication Number Publication Date
TW202034955A true TW202034955A (zh) 2020-10-01

Family

ID=71075816

Family Applications (1)

Application Number Title Priority Date Filing Date
TW108145197A TW202034955A (zh) 2018-12-10 2019-12-10 使用免疫調節治療癌症之新穎方法

Country Status (13)

Country Link
US (1) US20220089733A1 (https=)
EP (1) EP3893869A4 (https=)
JP (2) JP2022512158A (https=)
KR (1) KR20210102259A (https=)
CN (1) CN113260361A (https=)
AU (1) AU2019396206A1 (https=)
BR (1) BR112021011205A2 (https=)
CA (1) CA3121270A1 (https=)
IL (1) IL283742A (https=)
MX (1) MX2021006778A (https=)
SG (1) SG11202106129RA (https=)
TW (1) TW202034955A (https=)
WO (1) WO2020123496A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2991628C (en) 2015-07-16 2020-04-07 Bioxcel Therapeutics, Inc. A novel approach for treatment of cancer using immunomodulation
WO2021158884A1 (en) * 2020-02-07 2021-08-12 Bioxcel Therapeutics, Inc. Treatment regimen for cancer using immunomodulation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008033368A2 (en) * 2006-09-12 2008-03-20 Dara Biosciences, Inc. Boroproline compound and cytokine combination therapy
US9295731B2 (en) * 2013-04-01 2016-03-29 Mark Quang Nguyen Cleavable drug conjugates, compositions thereof and methods of use
CA2973040A1 (en) * 2015-01-09 2016-07-14 Mabimmune Diagnostics Ag Novel anti-fibroblast activation protein (fap) antibodies and uses derived thereof
CA2991628C (en) * 2015-07-16 2020-04-07 Bioxcel Therapeutics, Inc. A novel approach for treatment of cancer using immunomodulation
WO2017058881A1 (en) * 2015-09-28 2017-04-06 The Trustees Of Columbia University In The City Of New York Use of pentoxifylline with immune checkpoint-blockade therapies for the treatment of melanoma
US11613785B2 (en) * 2017-01-09 2023-03-28 Onkosxcel Therapeutics, Llc Predictive and diagnostic methods for prostate cancer
CN110914302A (zh) * 2017-06-01 2020-03-24 赛托姆克斯治疗学股份有限公司 可活化抗pdl1抗体及其使用方法

Also Published As

Publication number Publication date
JP2025156353A (ja) 2025-10-14
KR20210102259A (ko) 2021-08-19
EP3893869A1 (en) 2021-10-20
JP2022512158A (ja) 2022-02-02
WO2020123496A1 (en) 2020-06-18
CN113260361A (zh) 2021-08-13
BR112021011205A2 (pt) 2021-08-24
EP3893869A4 (en) 2022-08-17
SG11202106129RA (en) 2021-07-29
IL283742A (en) 2021-07-29
MX2021006778A (es) 2021-07-15
US20220089733A1 (en) 2022-03-24
AU2019396206A1 (en) 2021-06-17
CA3121270A1 (en) 2020-06-18

Similar Documents

Publication Publication Date Title
EP3570840B1 (en) Combinations of cabozantinib and atezolizumab for the treatment of castration-resistant prostate cancer
US12121566B2 (en) Methods for treating gout
JP2025156353A (ja) 免疫調節を使用したがんの治療のための新規アプローチ
WO2016168451A1 (en) Compositions for improving the pharmacokinetics and therapeutic index of cancer treatment
WO2024097667A1 (en) Methods for treating immune thrombocytopenia by administering (r)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l-yl]piperidine-l-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-l-yl]pent-2-enenitrile
US20230338402A1 (en) Treatment regimen for cancer using immunomodulation
WO2024155790A2 (en) Novel approach for treatment of cancer using immunomodulation
KR20260033049A (ko) 전립선암 치료 방법
CN118338901A (zh) 用于治疗癌症的cdk4抑制剂
Yang et al. HS-10296–a novel third generation EGFR tyrosine kinase inhibitor: results of the first-in-human phase 1 trial in patients with previously treated EGFR mutant advanced non-small-cell lung cancer
US20250339442A1 (en) Methods of treatment using a dual specificity tyrosine-phosphorylation-regulated kinase 1a (dyrk1a) inhibitor
US20240307397A1 (en) Pharmaceutical composition comprising pi3k and dna-pk dual inhibitor for preventing or treating peripheral t cell lymphoma
Siu Sitravatinib (MGCD516) and Nivolumab in Oral cavity cancer Window opportunity study (SNOW)
HK40110657A (zh) 用於治疗癌症的cdk4抑制剂
Zeng et al. Adebrelimab combined with anlotinib plus hepatic arterial infusion chemotherapy or intravenous chemotherapy for first-line treatment of advanced biliary tract cancer: protocol for a randomized open-label clinical study
WO2026076264A1 (en) Treatment of lymphomas using an ezh2 inhibitor
TW202612702A (zh) 吡啶并［２，３－ｄ］嘧啶－２（１Ｈ）－酮類衍生物聯合用藥在治療和預防腫瘤疾病中的用途
WO2025242031A1 (zh) 吡啶并[2,3-d]嘧啶-2(1H)-酮类衍生物联合用药在治疗和预防肿瘤疾病中的用途
HK40105135A (zh) 治疗癌症的卡博替尼与阿特珠单抗组合
NZ795674A (en) Combinations of cabozantinib and atezolizumab to treat cancer
HK40016051A (en) Combinations of cabozantinib and atezolizumab to treat cancer
HK40018507B (en) Combinations of cabozantinib and atezolizumab for the treatment of castration-resistant prostate cancer
HK40018507A (en) Combinations of cabozantinib and atezolizumab for the treatment of castration-resistant prostate cancer
Wei A Phase II, Single-center, Single-arm Clinical Trial on the Efficacy and Safety of Anti-PD-1 antibody (IBI308) Combined with Anlotinib for the Treatment of Recurrent or Advanced Endometrial Cancer